Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Olaparib, and Temozolomide in Recurrent Glioma
NCT05188508Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2022
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib, temozolomide in glioma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2022; status: recruiting.
02
Drugs
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05188508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05188508.